List of public comments to FDA and other agencies by UCSF faculty and fellows (and others) with links to the comments

Several people have asked us to collect all the public comments that we have submitted to the FDA.  We have also added comments submitted to other agencies on tobacco issues.  We will update this posting as new comments are submitted.  This post is current as of August 19, 2025.

August 2025: The National Youth Tobacco Survey and Proposed Emergency Regulations Implementing Assembly Bill 3218

California’s Unflavored Tobacco List and its implementing regulationsclose gaps in federal and state regulation of flavored tobacco products to better protect health and facilitate compliance and enforcement

The National Youth Tobacco Survey (NYTS) should be continued with consistent rigor, measures, and public access to data

November 2024: FDA and NIH Prioritization 

FDA, NIH, and other agencies must support research to increase reach and engagement in tobacco cessation interventions while also adopting comprehensive and integrated tobacco control policies that promote cessation to properly address health disparities among priority populations disproportionately impacted by smoking-related illness and death

FDA, NIH, and other agencies must address health disparities among priority populations that are disproportionately impacted by smokingrelated illness and death by not only supporting research that increases and broadens tobacco cessation interventions, but also by adopting comprehensive and integrated tobacco control policies that promote cessation

July 2024: Department of Justice’s proposed transfer of marijuana from Schedule I to Schedule III of the Controlled Substances Act

The Department of Justice and Drug Enforcement Agency should reclassify marijuana from Schedule I to Schedule III to allow consideration of the health, safety, and abuse liability impacts of cannabis and tobacco co-use along with cannabis use alone

The Department of Justice’s proposed transfer of marijuana from Schedule I to Schedule III of the Controlled Substances Act will facilitate research on the cardiovascular impacts of cannabis use

Because perceived harms of cannabis affect youth use, regulators must consider the impact of rescheduling cannabis from Schedule I to Schedule III on youth perceptions and use and design appropriate communications describing health risks

June/July 2024: Swedish Match Snus 2024 MRTP Renewal Applicaton

FDA should consider the significant public health issues, especially for youth, created by Philip Morris International’s co-marketing of its Swedish Match General Snus products with its Swedish Match ZYN oral nicotine products

FDA should not renew the Modified Risk Granted Order for eight Swedish Match General Snus products because as actually used by consumers, these products will not benefit the health of the population as a whole

FDA should not renew the Modified Risk Granted Order for eight Swedish Match General Snus modified risk tobacco product application for General Snus

FDA should consider the significant public health issues, especially for youth, created by PMI’s co-marketing of its Swedish Match General Snus products with its Swedish Match ZYN oral nicotine products

August 2023: Developing FDA’s Center for Tobacco Products’ Strategic Plan

CTP should finalize its updated list of Harmful and Potentially Harmful Constituents by December 2023

CTP should finalize the proposed rules prohibiting menthol in cigarettes and prohibiting characterizing flavors in cigars, and the rules should include menthol analogs with cooling agents that mimic menthol

FDA should prioritize direct measures of health and behavioral effects over indirect measures or assumptions in making regulatory decisions

Suggested approaches CTP to make new produce application process more efficient and effective, and better protect the health of youth and other priority populations and be more transparent.

CTP should advance and finalize a rule setting a product standard for a maximum allowable level of nicotine in tobacco products

CTP should actively integrate the relationship between cannabis and tobacco use into its tobacco regulation and proactively identify regulatory approaches from tobacco product regulation that can be applied to cannabis

August 2023: Draft HHS 2023 Framework to Support and Accelerate Smoking Cessation

HHS’s proposed Framework to Support and Accelerate Smoking Cessation is an important first step to addressing health disparities among populations disproportionately impacted by smoking-related illness and death.

May 2023: Requirements for Tobacco Product Manufacturing Practice

FDA’s proposed regulation establishes reasonable tobacco product manufacturing practice requirements that could help minimize the risks of products, especially to youth and young adults

June/August 2022: Tobacco Product Standard for Menthol in Cigarettes

Actual human disease data contradicts the low assumed e-cigarette risk FDA uses to justify an exception for “reduced risk” cigarettes in its product standard prohibiting menthol

FDA was correct in not quantifying consumer surplus in its analysis of the proposed standard for menthol in cigarette

FDA’s economic model underestimates the benefits of the proposed product standard prohibiting menthol in cigarettes, so the benefits would be even greater

FDA should not grant exemptions to the proposed standard on a case-by-case basis for certain cigarettes such as heated tobacco products or low nicotine cigarettes 

FDA should prohibit all menthol flavor additives, compounds, constituents, and ingredients in cigarettes, and should not limit the proposed standard to prohibiting menthol as a “characterizing flavor”

As a matter of health equity and social justice, FDA should immediately finalize and implement the proposed standard for menthol in cigarettes to reduce smoking-attributable deaths and health disparities among African Americans

Because of the tremendous health impacts that would accrue from the enactment of the proposed standard, we urge FDA to finalize the proposed rule and make it effective 90 days after the date of publication of the final rule.

The Food and Drug Administration’s proposed rule to prohibit menthol in cigarettes will reduce youth and young adult initiation rates of smoking cigarettes and significantly reduce premature deaths and illnesses related to tobacco use.

June/August 2022: Tobacco Product Standard for Characterizing Flavors in Cigars

FDA should extend the scope of the proposed flavor standard to prohibit flavors in all tobacco products, including e-cigarettes and smokeless tobacco, to make them less appealing to adolescents and young adults

FDA should extend the scope of the proposed standard prohibiting characterizing flavors in cigars to include e-cigarettes

FDA’s proposed rule prohibiting characterizing flavors in cigars will reduce their appeal and will therefore reduce initiation rates, reduce tobacco-related deaths and diseases, and reduce health disparities; however, greater benefits will be realized if FDA prohibits flavors as additives and extends the scope of the rule to waterpipe

FDA should finalize the proposed rule prohibiting characterizing flavors in cigars and make it effective 90 days after publication of the final rule.

FDA should deny any requests for extensions of time to submit public comments about the proposed rule on characterizing flavors in cigars.

February 2022: Validation and Verification of Analytical Testing Methods Used for Tobacco Products: Guidance for Industry

FDA’s draft guidance for industry on “Validation and Verification of Analytical Testing Methods used for Tobacco Products” provides information and recommendations related to the validation and verification of analytical test methods, including analytical testing of tobacco product constituents, ingredients, and additives, as well as stability testing of tobacco products.

December 2021: PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not adequately consider or address new published research on IQOS’s appeal to adolescents or young adults

The supplemental modified risk tobacco product application for IQOS 3 (sMRTPA) does not adequately address new published research and information on the appeal of IQOS 3 to youth, consumer perceptions of IQOS 3, or the likelihood that the proposed labeling and marketing will mislead consumers, especially youth. The sMRTPA also does not demonstrate benefits to individual or population health. Therefore, FDA should not issue an MRTP order for IQOS 3.

October 2021: IQOS 3 supplemental MRTP does not does not adequately address new published research and information on emissions

The supplemental modified risk tobacco product application for IQOS 3 does not adequately address new published research and information on emissions of HPHCs and other toxic substances in IQOS aerosol and does not demonstrate benefits to individual or population health, so FDA should not issue an exposure modification MRTP order for IQOS 3

September 2021: Letter Supporting Attorneys General's August 18, 2021 Letter to FDA

Letter from Dr. Pamela Ling to FDA Acting Commissioner Dr. Janet Woodcock and Center for Tobacco Products Mitchell Zeller, supporting 31 Attorneys General's letter urging FDA to eliminate youth-appealing flavors (including menthol) in all tobacco products, limit nicotine levels, and restrict marketing that targets youth.

September 2021: FDA should not issue an exposure modification MRTP order for IQOS 3

The supplemental modified risk tobacco product application for IQOS 3 (sMRTPA) does not address new published research and information on the risks to vascular endothelial function from exposure to IQOS aerosol and does not demonstrate benefits to individual or population health.

July 2021: Request to extend the public comment period for the IQOS 3 MRTPA

UCSF TCORS submitted a request to the FDA to extend the public comment period for the IQOS 3 MRTPA by at least 30 days in compliance with the Family Smoking Prevention and Tobacco Control Act. 

July 2021: More Materials from IQOS 3 MRTP Application Posted, Comment Deadline Extended

In response to a request from UCSF TCORS, the FDA extended the comment period on Philip Morris Products S.A.’s (PMPSA) modified risk tobacco product (MRTP) application for the IQOS 3 System Holder & Charger to provide time for the public to review application materials that were not previously posted. 

March 2021: USPS Proposed Restriction on mailing e-cigarettes and components

The Postal Service’s proposed revision of Publication 52, Hazardous, Restricted, and Perishable Mail, to restrict the mailing of e-cigarettes and e-cigarette components, liquids, parts and accessories, is a positive step toward protecting youth

December 2020: FDA's draft guidance on how to design and conduct Tobacco Product perception and intention studies

FDA’s draft guidance on Principles for Designing and Conducting Tobacco Product Perception and Intention Studies appropriately highlights the importance of determining whether consumers understand the risks of new tobacco products and modified risk claims

April 2020: Avoiding EVALI

In identifying additives and design elements known to increase severe lung disease, FDA should not create a "safe harbor" list for e-cigarettes

February 2020: 22nd Century VLN MRTP Application

Letter to Mitch Zeller raising question about the VLM PMTA

22^nd Century’s VLN cigarettes marketing with modified exposure claims has not been tested and will likely be appealing to youth and young adults

22^nd Century’s MRTP application for its VLN cigarettes should be denied because it does not adequately address how its product would be actually used and because the modified exposure claim misleads consumers to believe this product is less harmful than conventional cigarettes

November 2019: Premarket Tobacco Product Applications and Recordkeeping Requirements

Premarket Tobacco Product Applications and Recordkeeping Requirements -- Proposed Rule

October 2019: Comment on FDA's proposed text and graphic warning labels

FDA’s proposed warningsand accompanying color images will promote public understanding of the negative health consequences of smoking and should be implemented with some improvements

October 2019: FDA request for comments on list of Harmful and Potentially Harmful Constituents

In addition to the 19 constituents FDA proposes to add to the list of Harmful and Potentially Harmful Constituents, FDA should also add compounds that may be carcinogenic or cause pulmonary or cardiovascular harms when inhaled, especially oils and chemicals and chemical classes found in e-cigarette flavorants, and FDA should use as additional criteria California’s Proposition 65 list of carcinogens and reproductive toxicants and the California Air Resources Board’s list of Toxicant Air Contaminants

July 2019: FDA request for comment on cannabis

Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds

March 2019: FDA request for comment on changing the e-cigarette nonenforcement period

FDA’s proposed modifications to its compliance policy for e-cigarettes leaves millions of youth at risk for starting to use e-cigarettes; FDA needs to remove these products from the market now and clamp down on illegal therapeutic and modified risk claims

February/June 2019: FDA Request for How to Treat Youth Addicted to Nicotine

FDA must address youth tobacco addiction now by restricting technology and marketing strategies that appeal to and addict youth

FDA should use its regulatory authority and take immediate steps to tackle the youth e-cigarette epidemic

FDA must use its existing authority to combat the youth e-cigarette use epidemic by preventing addiction now, rather than by seeking to treat it after the fact

February 2019: CDC request for how to improve support for state and local tobacco control programs

CDC should promote strategies proven effective at the local and state levels including banning all flavored tobacco products, improving community education, and engaging vulnerable populations to prevent youth initiation to tobacco, ensure smokefree air, and eliminate tobacco-related disparities

January 2019: US Smokeless Tobacco (Altria) request to sell Copenhagen Snuff with reduced risk claims

FDA should not permit the U.S. Smokeless Tobacco Company to market Copenhagen Snuff with modified risk claims

September 2018/May 2019: Canadian Ministry of Health Comments on E-cigarettes

Consultation on Potential Regulatory Measures to Reduce Youth Access and Appeal of Vaping Products: Evidence and Recommendations from the U.S. Experience

Canadian Ministry of Health proposes to authorize e-cig sellers to make claims that ignore recent understanding of health risks

Comment by Physicians for a Smokefree Canada

August/September 2018: RJ Reynolds MRTP application for snus

COMMENT PREPARED AFTER THE TPSAC MEETIING ON CAMEL SNUS: RJR failed to demonstrate that Camel Snus, as actually used by consumers, will significantly reduce harm to individuals or benefit population health.  FDA should not issue an MRTP order allowing RJR to market Camel Snus with modified risk claims

Summary of the 5 public comments UCSF TCORS submitted to FDA on why FDA should not approve allowing RJR to claim Camel Snus is a less dangerous product

Clinical Trials and Observational Epidemiology Indicate that Allowing Snus to be Marketed with Modified Risk Claims is Unlikely to Confer Population Benefit and May Cause Harm by Depressing Smoking Cessation

Reynolds’ own data do not support their claim that because exclusive users of Camel Snus experience lower levels of exposure to some toxicants, they will reduce their risk of harm from lung cancer, oral cancer, respiratory disease, and heart disease

R.J. Reynolds Tobacco Company’s Application for Six Camel SNUS Smokeless Tobacco Minimizes its Appeal to Adolescents and the Likelihood that Youth and Adolescents Will Initiate Smokeless Tobacco or Smokeless Tobacco with Other Products

RJR consumer perceptions studies are poorly designed and fail to provide sufficient evidence to evaluate the effects the proposed modified risk advertisements on consumer comprehension and behavioral intentions

The Dynamic Population Modeler (+1) Used to Show Population Health Benefits Does Not Justify Issuing a MRTP Order for Camel SNUS Products

Letter to Mitch Zeller et al. at FDA re questions we suggest FDA pose to TPSAC regarding Camel Snus MRTP application
 
Letter to FDA protesting the way that they are handling public comment in RJR snus MRTP

July 2018: Premium Cigars

FDA Should Not Create a Separate Category for So-Called “Premium Cigars” Because it has Already Correctly Concluded that there is No Appropriate Public Health Justification to Exclude Premium Cigars from Regulation

July 2018: FDA Advanced Notice of Proposed Rulemaking on a Nicotine Product Standard

FDA Tobacco Product Standard for Nicotine Level of Combusted Cigarettes: Protecting Against Unintended Consequences by Expanding the Scope of the Rule to All Inhaled Recreational Nicotine Products

FDA Should Set a Nicotine Product Standard Level to be Achieved in a Single Step for All Combusted Tobacco Products

The FDA needs to look beyond nicotine alone in developing its standard for nicotine delivery in tobacco products

Tobacco Product Standard for Nicotine Level of Combusted Cigarettes

May 2018: FDA Advanced Notice of Proposed Rulemaking on Flavors

FDA should implement its proposed rule that manufacturers must present scientific evidence demonstrating that any flavored tobacco product is appropriate for the protection of the public health before receiving marketing authorization to use that flavor
 
April 2018: Nicotine Steering Committee

FDA’s Nicotine Steering Committee should develop policies, regulations, and procedures that promote cessation and increase the use of proven therapies

FDA Should Facilitate Investigational New Drug Applications (IND) for Commercially Available Electronic Nicotine Delivery Devices

February 2018: FDA comprehensive nicotine policy

The FDA should not adopt the nicotine “harm reduction” paradigm because doing so is likely to increase the amount of smoking-caused disease and death

January 2018: FDA consideration of PMI IQOS premarket approval application

FDA should not grant PMI's Premarket Tobacco Product Application for IQOS

January 2018: CDC request for comments on strategies to improved smoking cessation
 
CDC should employ evidence-based strategies to help people quit using tobacco that support the initiation of quit attempts and maintaining long-term abstinence, including:  social media interventions, clinician-extender or point-of-care technology tools, interactive voice response systems, market segmentation, insurance coverage for cessation treatment, tobacco-free policies in substance abuse treatment, mental health and other institutional settings including prisons and military settings.
 
December 2017: Tobacco Product Manufacturing Practice; Request for Comments
 
FDA should reject the tobacco industry’s efforts to guide e-cigarette manufacturing standards and instead formulate their own science-driven tough regulations to protect public health
 
2017-2020: Philip Morris International MRTP application for iQOS

FDA should not authorize Philip Morris International to market IQOS with claims of reduced risk or reduced exposure  

PMIs’ mouse study demonstrates increased morbidity and mortality in mice exposed to IQOS aerosol, and PMI’s December 20, 2019 response to FDA’s Request for Information fails to show otherwise

PMI’s 6-month study “Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks (ZRHR-ERS-09 US) submitted in  PMI IQOS MRTP June 8, 2018 amendment to FDA-2017-D-3001-0002 does not support claims of reduced risk

PMI’s December 22, 2017 amendment to its IQOS MRTP application failed to address concerns about dual use, flavors, risk perceptions, and its Population Health Impact Model  

Letter to FDA TPSAC urging them to delay action on  IQOS until the record is closed and they can consider public comments
 
Public comment submitting Reuters story on PMI irregulatities in IQOS clinical studies to PMI MRTP docket
 
Letter to FDA protesting public comment period for IQOS; says comment period should be 180 days after full application is posted
 
Because PMI has not demonstrated that IQOS is associated with lower risks, FDA should not permit modified exposure claims, because such claims are likely to be misunderstood as modified risk claims
 
Detailed analysis of the Executive Summary (Section 2.7) submitted by Philip Morris International in support of its MRTP application for IQOS
 
The evidence cited in PMI’s MRTP Application indicates  that the proposed labeling and warnings for IQOS will mislead consumers, particularly youth, about the product
 
PMI’s MRTP Application for IQOS Does Not Consider IQOS’s Appeal to Youth or Adolescents, or the Likelihood that Youth and Adolescents will Initiate Tobacco Use with IQOS or Use IQOS with Other Tobacco Products
 
PMI’s MRTP application for IQOS does not adequately evaluate potential for liver totoxicity risk
 
IQOS emissions create risks of immunosuppression and pulmonary toxicity, so FDA should not issue an order permitting IQOS to be labeled or marketed with reduced risk claims

Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical studies to describe exposure to toxicants during dual use with other tobacco products, FDA must deny PMI’s application
 
Philip Morris’s Population Health Impact Model Based on Questionable Assumptions and Insufficient Health Impact Measures Does Not Adequately Support its MRTP Application
 
The evidence PMI presents in its MRTP application for IQOS is misleading and does not support the conclusion that IQOS will not harm endothelial function; independent research done in a more relevant physiological model shows that IQOS harms endothelial function as much as conventional cigarettes
 
PMI’s Own Data on Biomarkers of Potential Harm in Americans Show that IQOS is Not Detectably Different from Conventional Cigs
 
FDA needs to extend the public comment period on PM MRTP for iQOS for 180 days after the FULL application is public
 
November 2017-August 2018: California Regulations to Implement Legalized Marijuana

Incorporating best practices from public administration and public-health oriented restrictions into California’s cannabis regulations is necessary to protect public health by restricting conflicts of interest and revolving door abuses, imposing environmentally sound exit packaging requirements limiting the use of single-use plastic products, and clarifying the daily sale limit for edibles containing concentrates

Incorporating best practices from tobacco control into California’s cannabis regulations is necessary to protect public health by restricting harmful product formulations, ensuring industry compliance and enforcement transparency, providing more complete and accurate information to consumers, and preventing abusive industry marketing tactics
 
BCC’s proposed daily limit is too permissive and will impose unnecessary risks on the health of Californians
 
Incorporating public health best practices from tobacco and alcohol regulation is necessary to protect public health by providing more information to consumers, restricting harmful formulations, and preventing abusive industry marketing tactics
 
May 2017: FDA’s Proposed Collection of Information on the Experimental Study on Warning Statements for Cigarette Graphic Health Warnings
 
FDA’s Proposed Collection of Information on the Experimental Study on Warning Statements for Cigarette Graphic Health Warnings Should be Addressing the Graphic Images, not Merely the Textual Statements
 
March 2017: Proposed NNN Product Standard
 
The FDA’s Proposed Tobacco Product Standard Limiting NNN Levels in Finished Smokeless Tobacco Products is Well-Justified, but the Regulatory Impact Analysis Understates Benefits and Overstates Costs
 
February 2017: Tobacco industry request to extend comment period for NNN product standard for smokeless tobacco
 
FDA Should Not Extend the Comment Period for its Proposed Product Standard Limiting NNN Levels in Finished Smokeless Tobacco
 
November 2016- April 2018: FDA request for comments on Listing of Ingredients in Tobacco Products – Revised Draft Guidance for Industry

FDA should revise its new guidance on listing of ingredients in tobacco products to require disclosure of all ingredients that can become toxic during normal use
 
Listing of Ingredients in Tobacco Products – Revised Draft Guidance for Industry
 
2016: FDA request for comments on waterpipes and waterpipe tobacco
 
FDA should regulate the manufacturing and marketing of hookah tobacco to prevent misperceptions of harm and widespread use among youth and young adults
 
September 2016: FDA Warning Label Requirements for Cigars
 
FDA’s Draft Guidance on Submission of Warning Plans for Cigars Exposes Shortcomings in Cigar Warnings Required by Final Rule
 
January 2016: HUD proposal to make public housing smokefree
 
Comment on HUD’s proposed rule Instituting smoke-free public housing Docket No. FR 5597-P-02
 
Comment on Regulatory Impact Analysis for HUD Proposed Rule Instituting Smoke-Free Public Housing Docket No. FR 5597-P-02
 
December 2015: FTC collection and release of data on e-cigarette marketing and promotion
 
Detailed information and reports on electronic cigarette marketing and sales is essential for understanding the skyrocketing popularity and use of various electronic cigarette products among youth and young adults
 
November 2015: Investigational drug use of of tobacco products
 
UCSF comment on FDA draft guidance on investigational use of tobacco products
 
November 2015: Which part of FDA should be responsible for regulating different tobacco products
 
UCSF TCORS public comment to FDA on when tobacco products should be regulated as drugs/devices or by CTP
 
August 2015: Liquid nicotine in e-cigarettes and nicotine in other novel products
 
UCSF and California Poison Control Centers response to FDA questions on liquid nicotine products
 
April 2015: FDA's list of questions regarding e-cigarettes
 
UCSF TCORS Responses to FDA Questions on E-Cigarettes and Public Health (Docket Number FDA-2014-N-1936)
 
Two more studies show ecigs depress quitting
 
2014-2019: UCSF public comments to FDA on Swedish Match MRTP application

Swedish Match's revised MRTP application didn't adequately address FDA's questions; FDA should deny its application to make reduced risk claims

FDA should require that all communications from tobacco manufacturers on MRTPs be done in a way that narrowly target smokers
 
Swedish Match’s Consumer Perception Study Provides No Evidence for the Population-Level Effects of Modified Snus Labels
 
FDA should deny Swedish Match request to change snus warning label: US is not Sweden
 
Swedish Match’s claim that perceptions of health risks of snus are exaggerated is likely incorrect
 
2014: UCSF comments on Request for Information on Psychosocial Predictors of Uptake of Tobacco and Other Products
 
RJ Reynold’s Unpublished Randomized Controlled Trial Finds that Camel Snus is Not Effective for Smoking Cessation
 
2014: UCSF Comments on the Deeming Rule 
 
Doonesbury figured out that big tobacco would benefit from OIRA's cost-benefit models 19 years ago
 
Entire 1995 Doonesbury series on Mr. Butts and Regulatory Reform (series of comics)
 
FDA Should Use the Public Health Standard Mandated by Congress, Not a Cost-Benefit Analysis, to Evaluate Proposed Regulations
 
FDA Should Prohibit Flavors in all Tobacco Products including Electronic Cigarettes (new data)
 
Recent Research, some conducted by the FDA, Reinforces Need for Regulation of ALL Tobacco Products to Protect Health
 
FDA should prohibit of use of flavors in deemed tobacco products as part of the current rulemaking
 
FDA Should Prohibit All Non-Face-to-Face (Including Internet) Sales of Tobacco Products as FDA Originally Proposed to the OMB
 
E-Cigarette Makers Are in an Arms Race for Exotic Vapor Flavors
 
FDA Should Not Exclude Accessories from the Scope of the Deeming Rule
 
The Regulatory Impact Analysis Must Consider the Benefits of the Likelihood that the Regulated Companies will Pass the Costs of Compliance on to Smokers, which Will Raise the Cost of the Regulated Products, thereby Reducing Consumption and Improving Health
 
The Regulatory Impact Analysis Fails to Adequately Document the Sources for the Benefit and Cost Estimates upon Which it is Based
 
FDA Should Deem Hookah Tobacco, Hookah Device, and Hookah Charcoal as a Tobacco Product
 
Child resistant packaging of electronic cigarette devices and refill liquid containers containing nicotine to prevent childhood poisoning
 
More evidence against “continuum of risk” related to heart disease
 
The FDA should follow the advice of the 129 public health and medical authorities outlined in the attached letter that they sent to WHO Director General Margaret Chan regarding making evidence-based decisions about regulation of e-cigarettes. 
 
FDA Should Not Extend the Compliance Period for Marketing Applications and Other Submissions
 
FDA should not make regulatory decisions based on the "continuum of risk" theory until it has affirmative evidence that, as actually used, e-cigarettes or other tobacco products lower population risk
 
Evidence that e-cigarette aerosol has the same effects on an important measure of lung function as cigarette smoke undermines the assumption that e-cigarettes are uniformly less risky than conventional cigarettes
 
The FDA’s Proposed Warnings on Addiction are Inadequate and Do Not Reflect Current Understanding of Appropriate Messaging on Addiction
 
FDA’s Proposed Warning Statements Are Weak and Ineffective both in Form and Content and Should Be Replaced with Effective Messages
 
The “Continuum of Risk” Must Include Cardiovascular Disease
 
FDA Should Restrict E-cigarette Marketing to Protect Youth as Part of the Currently Proposed Regulation
 
Responses to common undocumented assertions about e-cigarettes for harm reduction
 
FDA’s Proposed Exception for Premium Cigars and Weak Warning Labels for Cigars Do Not Protect the Public Health
 
The Proposed Two Year Phase in for Requiring Premarket Approval of Newly Deemed Tobacco Products is Too Long; 6 Months Would be More Appropriate
 
FDA Should Prohibit Flavors in all Tobacco Products in the Current Rule Making
 
FDA Should Prohibit E-cigarette Marketing that Promotes False Health Claims
 
Resubmission of 2013 comment documenting ecigarette cessation claims in their marketing
 
FDA’s Proposed Exception for Premium Cigars (Option 2) Does Not Protect the Public Health and Should Be Rejected
 
Broad Range of Economists Agree that FDA's Use of Consumer Surplus Is Wrong, Including Jonathan Gruber, Whose Work FDA Cites as Justification for Doing So
 
Lorillard Admits Flavored E-Cigarettes Attract Youth; FDA Should Prohibit Flavors As Part Of The Current Rulemaking
 
FDA inappropriately discounts health benefits of regulating ecigs and cigars by 70% because of lost pleasure of smoking
 
FDA should deny industry requests to extend public comment on deeming; granting industry request = 26,000 more kids trying ecigs
 
UCSF economists critique FDA cost-benefit analysis of FDA deeming rule
 
FDA to kids: Not 18? No problem! Buy your e-cigs (and cigars and other tobacco products) online!
 
FDA ignored information on internet sales submitted in response to 2011 ANPRM in deeming rule
 
Summary of scientific evidence on e-cigarettes submitted to FDA
 
FDA economic model used in Regulatory Impact Analysis underestimates benefits by ignoring short term effects of smoking
 
Contradicting the science it cites, FDA decides against warning cigar users about reproductive dangers
 
FDA should use information in the 2014 Surgeon General Report when finalizing its deeming rule